Youtube Pro Stock Picks

Click here to search for stock quotes, financial statistics and more.

or

Life Sciences

MSCL stock
Analysts Life Sciences MSCL
Satellos Bioscience is undervalued, Leede says

Leede Financial analyst Douglas Loe initiated coverage of Satellos Bioscience (Satellos Bioscience Stock Quote, Chart, News, Analysts, Financials TSX:MSCL) on January 28 with a “Speculative Buy” rating and a one-year price target of $2.25, citing the company’s differentiated approach to treating Duchenne muscular dystrophy (DMD) and multiple upcoming clinical catalysts. Satellos is a Toronto-based, clinical-stage biotechnology […]

TEVA Pharma
Analysts Life Sciences TEVA
This pharma stock “is beating everything”, investor says

BNN Bloomberg Market Call guest Colin Cieszynski said Teva Pharmaceutical Industries (Teva Pharmaceutical Industries Stock Quote, Chart, News, Analysts, Financials NYSE:TEVA) has emerged as a standout performer amid a broader rotation into drug stocks, driven by strong price momentum and relative strength rather than company-specific catalysts. Speaking on the Jan. 9 program, the SIA Wealth […]

Share Tweet linked In Share

Get Stock Picks from the Pros.
In your Inbox.

On Thursday, IMRIS (TSX:IM) reported its Q2, 2912 results. The company lost $4.28-million on revenue...

Oncolytics Biotech (TSX:ONC) last week reported its Q2 results. The company lost $10.17-million, or ...

Shares of TS03 (TSX:TOS) are climbing today after the company announced it had signed a letter of in...

New Centric Health CEO David Cutler. Byron Capital analyst Douglas Loe believes Cutler has the necessary experience in the public markets and in the long-term care/eldercare, a market he believes Centric should pursue aggressively.

Last Monday, Centric Health (TSX:CHH) appointed David Cutler as its new President and CEO. The compa...

AEterna Zentaris is facing a class-action suit over its lead offering, perifosine, which in April failed to meet its primary endpoint. But CEO Jürgen Engel is buying shares of the company in the open market.

On April 2nd, shareholders of Quebec-based oncology/endocrinology drug maker AEterna Zentaris (TSX:A...

Medicago

Is Quebec’s Medicago preparing us for a future pandemic response? One of the best thrillers in...

A recent report from MarketResearch.com said the U.S. EMR market is expected to grow from $2.17-billion in 2009 to more than $6-billion in 2015; an estimated compound annual growth rate of 18.1%

Since 2008, Kelowna-based QHR Technologies (TSXV:QHR) has grown from just $6.52-million in revenue t...

Byron Capital analyst Douglas Loe says the lawsuit between Tekmira and Alnylam, which is scheduled to be heard in Massachusetts court in October presents a

Last week, Alnylam Pharmaceuticals (NASDAQ:ALNY) announced that it reported positive results from a ...

After announcing the close of a financing Friday, management of Vancouver-based iCO Therapeutics bought shares of the company in the open market this week.

After tailing off after the financial crisis of 2008, Vancouver-based iCo Therapeutics (TSXV:ICO) ha...

Amid a massive restructuring, Vancouver's QLT today announced that its CEO, Robert Butchofsky will be leaving the company.

The recently appointed board of Vancouver-based QLT (TSX:ALT) today issued a letter to shareholders ...

The TMX Group, the company that owns the Toronto Stock Exchange, said it would help development of an already under development on-line investing platform to connect impact ventures, funds, investors and service providers.

The TMX Group today announced it would contribute financing and resources to Toronto’s MaRS Ce...

Investors haven’t been crying over the performance of TearLab, shares of the company are up mo...

iCo Therapeutics pipeline. The Vancouver-based company, which was founded in 2005, is a biotech that focuses on redosing or reformulating drugs that already have a clinical history.

Shares of Vancouver-based iCo Therapeutics (TSX:ICO) hit a fifty-two week high Friday as shareholder...

Byron Capital healthcare analyst Douglas Loe says data coming out of ENDO, the Endocrine Society conference that wrapped up yesterday in Houston, is incongruous with the Theratechnologies E.U. regulatory challenges.

ENDO, the annual meeting of The Endocrine Society wrapped up its 2012 session in Houston yesterday. ...

Byron Capital Healthcare analyst Douglas Loe says the reason for Ferrer's withdrawal in Europe, concerns about long-term cardiovascular safety concerns from elevating IGF-1 blood levels generated by Egrifta use, is particularly bad.

Bad news for shareholders of Theratechnologies (TSX:TH) today. Shares of the Quebec-based biotech we...

The ribbon cutting ceremony at the Archer Daniels Midland Clarisoy plant in Decatur, Illinois.

With a burgeoning Chinese middle-class, the story of increased worldwide demand for food, particular...

Beware the Ides of…April and May? Bad news for shareholders of AEterna Zentaris (TSX:AEZ) has ...

After receiving FDA approval for acne treatment Absorica Monday, Cipher Pharmaceuticals will work with distribution partner Ranbaxy Laboratories to prepare for its U.S. launch.

Shares of Cipher Pharmaceuticals (TSX:DND) are pulling back today, but investor interest in the comp...

Share Tweet linked In Share

Get Stock Picks from the Pros. In your Inbox.

TRENDING

All Trending →
MDA stock

Analyst raises target on MDA Space to street-high $60.00

 February 2, 2026
PLTR stock

Palantir is going to drop like a rock, RBC says

 January 27, 2026
CLS stock

Should you sell your Celestica stock?

 January 22, 2026
MDA stock

Why MDA Space is worth more than you think

 January 20, 2026
RIOT stock

This crypto stock just won a big price target raise

 January 20, 2026